Academic Journal
View in EDS

SGLT2 Inhibitors in Nephrolithiasis: Emerging Evidence and What Urologists Need to Know.

Bibliographic Details
Title: SGLT2 Inhibitors in Nephrolithiasis: Emerging Evidence and What Urologists Need to Know.
Authors: Ivănuță M; Department of Urology, Grigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania.; Department of Urology, 'Dr. C.I. Parhon' Clinical Hospital, 700503 Iasi, Romania.; Center for Morphological and Spectroscopic Analysis of Urinary Stones' Michel Daudon', 700503 Iasi, Romania., Puia D; Department of Urology, Grigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania.; Department of Urology, 'Dr. C.I. Parhon' Clinical Hospital, 700503 Iasi, Romania.; Center for Morphological and Spectroscopic Analysis of Urinary Stones' Michel Daudon', 700503 Iasi, Romania., Ivănuță AM; Emergency Care Department, 'Sf. Spiridon' County University Emergency Hospital, 700111 Iasi, Romania., Haută A; Department of Urology, Grigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania.; Department of Urology, 'Dr. C.I. Parhon' Clinical Hospital, 700503 Iasi, Romania., Nistor I; Department of Urology, Grigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania.; Department of Nephrology, 'Dr. C.I. Parhon' Clinical Hospital, 700503 Iasi, Romania., Pricop C; Department of Urology, Grigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania.; Department of Urology, 'Dr. C.I. Parhon' Clinical Hospital, 700503 Iasi, Romania.; Center for Morphological and Spectroscopic Analysis of Urinary Stones' Michel Daudon', 700503 Iasi, Romania.
Source: Medical sciences (Basel, Switzerland) [Med Sci (Basel)] 2026 Sep 09; Vol. 14 (5). Date of Electronic Publication: 2026 Sep 09.
Publication Type: Journal Article; Review
Language: English
Journal Info: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101629322 Publication Model: Electronic Cited Medium: Internet ISSN: 2076-3271 (Electronic) Linking ISSN: 20763271 NLM ISO Abbreviation: Med Sci (Basel) Subsets: MEDLINE
Imprint Name(s): Original Publication: Basel, Switzerland : MDPI AG, [2013]-
MeSH Terms: Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use , Sodium-Glucose Transporter 2 Inhibitors*/pharmacology , Sodium-Glucose Transporter 2 Inhibitors*/adverse effects , Nephrolithiasis*/drug therapy, Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/complications ; Humans
Abstract: Background: Nephrolithiasis frequently coexists with type 2 diabetes, obesity, gout, chronic kidney disease, and other cardiometabolic disorders. Sodium-glucose cotransporter 2 (SGLT2) inhibitors may influence stone formation through effects on glucosuria, natriuresis, urine volume, urinary citrate, pH, urate handling, and relative supersaturation. This review aimed to examine the current mechanistic, biochemical, and clinical evidence linking SGLT2 inhibition to nephrolithiasis, with particular attention to its relevance for urological practice.
Methods: A clinically oriented narrative review was conducted using PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar. The final search was performed on 1 July 2026. A total of 15 studies were included. Randomised trials, pooled and post hoc analyses, observational and comparative-effectiveness studies, meta-analyses, human mechanistic studies, and relevant experimental investigations were considered. Evidence was synthesised narratively according to biological mechanisms, urinary chemistry and relative supersaturation, randomised evidence, and observational clinical outcomes. Clinical stone events were analysed separately from surrogate urinary endpoints.
Results: SGLT2 inhibition is associated with reproducible increases in urinary citrate and variable effects on urine volume, urinary pH, and the excretion of calcium, phosphate, and urate. Short-term mechanistic studies suggest reductions in calcium phosphate supersaturation and, in selected uric acid stone formers, uric acid supersaturation, whereas effects on calcium oxalate supersaturation remain inconsistent. Observational studies and secondary analyses of randomised trials generally indicate fewer nephrolithiasis events among SGLT2 inhibitor users; however, most outcomes were based on adverse-event reporting or administrative codes and lacked stone composition, standardised imaging, urinary phenotyping, and recurrence adjudication.
Conclusions: SGLT2 inhibitors may favourably modify selected lithogenic pathways, but their effects appear phenotype-dependent and have not yet been shown to directly prevent stone recurrence. They should not be initiated solely for the prevention of nephrolithiasis. In patients with established cardiovascular, renal, or metabolic indications, their potential urinary effects may represent an additional benefit. Dedicated long-term randomised studies with stone-specific endpoints are required.
References: Int Heart J. 2023;64(2):246-251. (PMID: 37005318)
Exp Ther Med. 2022 Oct 10;24(6):715. (PMID: 36349061)
Diabetologia. 2021 Jul;64(7):1563-1571. (PMID: 33715024)
Curr Opin Nephrol Hypertens. 2020 Sep;29(5):523-530. (PMID: 32701600)
J Clin Endocrinol Metab. 2022 Jun 16;107(7):e3003-e3007. (PMID: 35290464)
Diabetes Res Clin Pract. 2019 Sep;155:107808. (PMID: 31401152)
Urolithiasis. 2026 May 26;54(1):. (PMID: 42191892)
Kidney360. 2026 Mar 1;7(3):633-641. (PMID: 41117521)
Cell Rep Med. 2024 Aug 20;5(8):101690. (PMID: 39168099)
J Bras Nefrol. 2024 Jul-Sep;46(3):e20230146. (PMID: 38498673)
Sci Rep. 2019 Sep 10;9(1):13009. (PMID: 31506585)
PLoS One. 2025 Apr 24;20(4):e0322034. (PMID: 40273182)
Discoveries (Craiova). 2022 Sep 30;10(3):e152. (PMID: 36540089)
J Gerontol A Biol Sci Med Sci. 2024 Feb 1;79(2):. (PMID: 37527836)
Nephrol Dial Transplant. 2025 Apr 01;40(4):671-678. (PMID: 39113274)
Pharmacol Res. 2022 Dec;186:106524. (PMID: 36349594)
BMC Cardiovasc Disord. 2026 Feb 14;26(1):. (PMID: 41691153)
Eur J Clin Pharmacol. 2026 Mar 11;82(4):. (PMID: 41811498)
Electrolyte Blood Press. 2025 Dec;23(2):23-30. (PMID: 41541562)
Clin Pharmacol Ther. 2025 Jun;117(6):1775-1783. (PMID: 40059622)
Kidney Int Rep. 2023 Feb 03;8(4):925-928. (PMID: 37069977)
Diabetes Obes Metab. 2015 Apr;17(4):426-9. (PMID: 25600248)
BMJ. 2024 Oct 30;387:e080035. (PMID: 39477370)
Arch Ital Urol Androl. 2015 Jul 07;87(2):105-20. (PMID: 26150027)
Clin Transl Sci. 2026 Jun;19(6):e70594. (PMID: 42144570)
Nat Med. 2025 Jan;31(1):286-293. (PMID: 39747681)
Annu Rev Med. 2026 Jan;77(1):363-379. (PMID: 41592925)
Biochim Biophys Acta. 2016 Jun;1862(6):1055-62. (PMID: 26854734)
J Clin Med. 2024 Oct 14;13(20):. (PMID: 39458060)
J Am Soc Nephrol. 2022 Jun;33(6):1073-1075. (PMID: 35387874)
Urolithiasis. 2023 Jan 17;51(1):33. (PMID: 36648596)
J Clin Med. 2024 Oct 09;13(19):. (PMID: 39408078)
Diabetes Res Clin Pract. 2025 Apr;222:112088. (PMID: 40057043)
Autophagy. 2025 Mar;21(3):583-597. (PMID: 39385699)
BMJ Open. 2022 Mar 14;12(3):e059073. (PMID: 35288397)
Diabetes Care. 2025 Feb 01;48(2):193-201. (PMID: 39666579)
Circulation. 2022 Oct 18;146(16):1210-1224. (PMID: 36029465)
Contributed Indexing: Keywords: metabolic syndrome; nephrolithiasis; pathophysiology; sodium–glucose cotransporter 2 inhibitors; urolithiasis
Substance Nomenclature: 0 (Sodium-Glucose Transporter 2 Inhibitors)
Entry Date(s): Date Created: 20260924 Date Completed: 20260924 Latest Revision: 20260928
Update Code: 20260928
PubMed Central ID: PMC13609381
DOI: 10.3390/medsci14050555
PMID: 42783428
Database: MEDLINE
FullText Text:
  Availability: 0
CustomLinks:
  – Url: https://resolver.ebsco.com/c/fiv2js/result?sid=EBSCO:cmedm&genre=article&issn=20763271&ISBN=&volume=14&issue=5&date=20260909&spage=&pages=&title=Medical sciences (Basel, Switzerland)&atitle=SGLT2%20Inhibitors%20in%20Nephrolithiasis%3A%20Emerging%20Evidence%20and%20What%20Urologists%20Need%20to%20Know.&aulast=Iv%C4%83nu%C8%9B%C4%83%20M&id=DOI:10.3390/medsci14050555
    Name: Full Text Finder (for New FTF UI) (ns324271)
    Category: fullText
    Text: Full Text Finder
    MouseOverText: Full Text Finder
Header DbId: cmedm
DbLabel: MEDLINE
An: 42783428
AccessLevel: 3
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: SGLT2 Inhibitors in Nephrolithiasis: Emerging Evidence and What Urologists Need to Know.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Ivănuță+M%22">Ivănuță M</searchLink>; Department of Urology, Grigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania.; Department of Urology, 'Dr. C.I. Parhon' Clinical Hospital, 700503 Iasi, Romania.; Center for Morphological and Spectroscopic Analysis of Urinary Stones' Michel Daudon', 700503 Iasi, Romania.<br /><searchLink fieldCode="AU" term="%22Puia+D%22">Puia D</searchLink>; Department of Urology, Grigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania.; Department of Urology, 'Dr. C.I. Parhon' Clinical Hospital, 700503 Iasi, Romania.; Center for Morphological and Spectroscopic Analysis of Urinary Stones' Michel Daudon', 700503 Iasi, Romania.<br /><searchLink fieldCode="AU" term="%22Ivănuță+AM%22">Ivănuță AM</searchLink>; Emergency Care Department, 'Sf. Spiridon' County University Emergency Hospital, 700111 Iasi, Romania.<br /><searchLink fieldCode="AU" term="%22Haută+A%22">Haută A</searchLink>; Department of Urology, Grigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania.; Department of Urology, 'Dr. C.I. Parhon' Clinical Hospital, 700503 Iasi, Romania.<br /><searchLink fieldCode="AU" term="%22Nistor+I%22">Nistor I</searchLink>; Department of Urology, Grigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania.; Department of Nephrology, 'Dr. C.I. Parhon' Clinical Hospital, 700503 Iasi, Romania.<br /><searchLink fieldCode="AU" term="%22Pricop+C%22">Pricop C</searchLink>; Department of Urology, Grigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania.; Department of Urology, 'Dr. C.I. Parhon' Clinical Hospital, 700503 Iasi, Romania.; Center for Morphological and Spectroscopic Analysis of Urinary Stones' Michel Daudon', 700503 Iasi, Romania.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101629322%22">Medical sciences (Basel, Switzerland)</searchLink> [Med Sci (Basel)] 2026 Sep 09; Vol. 14 (5). <i>Date of Electronic Publication: </i>2026 Sep 09.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Review
– Name: Language
  Label: Language
  Group: Lang
  Data: English
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22MDPI+AG%22">MDPI AG </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101629322 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2076-3271 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220763271%22">20763271 </searchLink><i>NLM ISO Abbreviation: </i>Med Sci (Basel) <i>Subsets: </i>MEDLINE
– Name: PublisherInfo
  Label: Imprint Name(s)
  Group: PubInfo
  Data: <i>Original Publication</i>: Basel, Switzerland : MDPI AG, [2013]-
– Name: SubjectMESH
  Label: MeSH Terms
  Group: Su
  Data: <searchLink fieldCode="MM" term="%22Sodium-Glucose+Transporter+2+Inhibitors%22">Sodium-Glucose Transporter 2 Inhibitors*</searchLink>/<searchLink fieldCode="MM" term="%22Sodium-Glucose+Transporter+2+Inhibitors+therapeutic+use%22">therapeutic use</searchLink> <br /><searchLink fieldCode="MM" term="%22Sodium-Glucose+Transporter+2+Inhibitors%22">Sodium-Glucose Transporter 2 Inhibitors*</searchLink>/<searchLink fieldCode="MM" term="%22Sodium-Glucose+Transporter+2+Inhibitors+pharmacology%22">pharmacology</searchLink> <br /><searchLink fieldCode="MM" term="%22Sodium-Glucose+Transporter+2+Inhibitors%22">Sodium-Glucose Transporter 2 Inhibitors*</searchLink>/<searchLink fieldCode="MM" term="%22Sodium-Glucose+Transporter+2+Inhibitors+adverse+effects%22">adverse effects</searchLink> <br /><searchLink fieldCode="MM" term="%22Nephrolithiasis%22">Nephrolithiasis*</searchLink>/<searchLink fieldCode="MM" term="%22Nephrolithiasis+drug+therapy%22">drug therapy</searchLink><br /><searchLink fieldCode="MH" term="%22Diabetes+Mellitus%2C+Type+2%22">Diabetes Mellitus, Type 2</searchLink>/<searchLink fieldCode="MH" term="%22Diabetes+Mellitus%2C+Type+2+drug+therapy%22">drug therapy</searchLink> ; <searchLink fieldCode="MH" term="%22Diabetes+Mellitus%2C+Type+2%22">Diabetes Mellitus, Type 2</searchLink>/<searchLink fieldCode="MH" term="%22Diabetes+Mellitus%2C+Type+2+complications%22">complications</searchLink> ; <searchLink fieldCode="MH" term="%22Humans%22">Humans</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Background: Nephrolithiasis frequently coexists with type 2 diabetes, obesity, gout, chronic kidney disease, and other cardiometabolic disorders. Sodium-glucose cotransporter 2 (SGLT2) inhibitors may influence stone formation through effects on glucosuria, natriuresis, urine volume, urinary citrate, pH, urate handling, and relative supersaturation. This review aimed to examine the current mechanistic, biochemical, and clinical evidence linking SGLT2 inhibition to nephrolithiasis, with particular attention to its relevance for urological practice.<br />Methods: A clinically oriented narrative review was conducted using PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar. The final search was performed on 1 July 2026. A total of 15 studies were included. Randomised trials, pooled and post hoc analyses, observational and comparative-effectiveness studies, meta-analyses, human mechanistic studies, and relevant experimental investigations were considered. Evidence was synthesised narratively according to biological mechanisms, urinary chemistry and relative supersaturation, randomised evidence, and observational clinical outcomes. Clinical stone events were analysed separately from surrogate urinary endpoints.<br />Results: SGLT2 inhibition is associated with reproducible increases in urinary citrate and variable effects on urine volume, urinary pH, and the excretion of calcium, phosphate, and urate. Short-term mechanistic studies suggest reductions in calcium phosphate supersaturation and, in selected uric acid stone formers, uric acid supersaturation, whereas effects on calcium oxalate supersaturation remain inconsistent. Observational studies and secondary analyses of randomised trials generally indicate fewer nephrolithiasis events among SGLT2 inhibitor users; however, most outcomes were based on adverse-event reporting or administrative codes and lacked stone composition, standardised imaging, urinary phenotyping, and recurrence adjudication.<br />Conclusions: SGLT2 inhibitors may favourably modify selected lithogenic pathways, but their effects appear phenotype-dependent and have not yet been shown to directly prevent stone recurrence. They should not be initiated solely for the prevention of nephrolithiasis. In patients with established cardiovascular, renal, or metabolic indications, their potential urinary effects may represent an additional benefit. Dedicated long-term randomised studies with stone-specific endpoints are required.
– Name: Ref
  Label: References
  Group: RefInfo
  Data: Int Heart J. 2023;64(2):246-251. (PMID: <searchLink fieldCode="PM" term="%2237005318%22">37005318)</searchLink><br />Exp Ther Med. 2022 Oct 10;24(6):715. (PMID: <searchLink fieldCode="PM" term="%2236349061%22">36349061)</searchLink><br />Diabetologia. 2021 Jul;64(7):1563-1571. (PMID: <searchLink fieldCode="PM" term="%2233715024%22">33715024)</searchLink><br />Curr Opin Nephrol Hypertens. 2020 Sep;29(5):523-530. (PMID: <searchLink fieldCode="PM" term="%2232701600%22">32701600)</searchLink><br />J Clin Endocrinol Metab. 2022 Jun 16;107(7):e3003-e3007. (PMID: <searchLink fieldCode="PM" term="%2235290464%22">35290464)</searchLink><br />Diabetes Res Clin Pract. 2019 Sep;155:107808. (PMID: <searchLink fieldCode="PM" term="%2231401152%22">31401152)</searchLink><br />Urolithiasis. 2026 May 26;54(1):. (PMID: <searchLink fieldCode="PM" term="%2242191892%22">42191892)</searchLink><br />Kidney360. 2026 Mar 1;7(3):633-641. (PMID: <searchLink fieldCode="PM" term="%2241117521%22">41117521)</searchLink><br />Cell Rep Med. 2024 Aug 20;5(8):101690. (PMID: <searchLink fieldCode="PM" term="%2239168099%22">39168099)</searchLink><br />J Bras Nefrol. 2024 Jul-Sep;46(3):e20230146. (PMID: <searchLink fieldCode="PM" term="%2238498673%22">38498673)</searchLink><br />Sci Rep. 2019 Sep 10;9(1):13009. (PMID: <searchLink fieldCode="PM" term="%2231506585%22">31506585)</searchLink><br />PLoS One. 2025 Apr 24;20(4):e0322034. (PMID: <searchLink fieldCode="PM" term="%2240273182%22">40273182)</searchLink><br />Discoveries (Craiova). 2022 Sep 30;10(3):e152. (PMID: <searchLink fieldCode="PM" term="%2236540089%22">36540089)</searchLink><br />J Gerontol A Biol Sci Med Sci. 2024 Feb 1;79(2):. (PMID: <searchLink fieldCode="PM" term="%2237527836%22">37527836)</searchLink><br />Nephrol Dial Transplant. 2025 Apr 01;40(4):671-678. (PMID: <searchLink fieldCode="PM" term="%2239113274%22">39113274)</searchLink><br />Pharmacol Res. 2022 Dec;186:106524. (PMID: <searchLink fieldCode="PM" term="%2236349594%22">36349594)</searchLink><br />BMC Cardiovasc Disord. 2026 Feb 14;26(1):. (PMID: <searchLink fieldCode="PM" term="%2241691153%22">41691153)</searchLink><br />Eur J Clin Pharmacol. 2026 Mar 11;82(4):. (PMID: <searchLink fieldCode="PM" term="%2241811498%22">41811498)</searchLink><br />Electrolyte Blood Press. 2025 Dec;23(2):23-30. (PMID: <searchLink fieldCode="PM" term="%2241541562%22">41541562)</searchLink><br />Clin Pharmacol Ther. 2025 Jun;117(6):1775-1783. (PMID: <searchLink fieldCode="PM" term="%2240059622%22">40059622)</searchLink><br />Kidney Int Rep. 2023 Feb 03;8(4):925-928. (PMID: <searchLink fieldCode="PM" term="%2237069977%22">37069977)</searchLink><br />Diabetes Obes Metab. 2015 Apr;17(4):426-9. (PMID: <searchLink fieldCode="PM" term="%2225600248%22">25600248)</searchLink><br />BMJ. 2024 Oct 30;387:e080035. (PMID: <searchLink fieldCode="PM" term="%2239477370%22">39477370)</searchLink><br />Arch Ital Urol Androl. 2015 Jul 07;87(2):105-20. (PMID: <searchLink fieldCode="PM" term="%2226150027%22">26150027)</searchLink><br />Clin Transl Sci. 2026 Jun;19(6):e70594. (PMID: <searchLink fieldCode="PM" term="%2242144570%22">42144570)</searchLink><br />Nat Med. 2025 Jan;31(1):286-293. (PMID: <searchLink fieldCode="PM" term="%2239747681%22">39747681)</searchLink><br />Annu Rev Med. 2026 Jan;77(1):363-379. (PMID: <searchLink fieldCode="PM" term="%2241592925%22">41592925)</searchLink><br />Biochim Biophys Acta. 2016 Jun;1862(6):1055-62. (PMID: <searchLink fieldCode="PM" term="%2226854734%22">26854734)</searchLink><br />J Clin Med. 2024 Oct 14;13(20):. (PMID: <searchLink fieldCode="PM" term="%2239458060%22">39458060)</searchLink><br />J Am Soc Nephrol. 2022 Jun;33(6):1073-1075. (PMID: <searchLink fieldCode="PM" term="%2235387874%22">35387874)</searchLink><br />Urolithiasis. 2023 Jan 17;51(1):33. (PMID: <searchLink fieldCode="PM" term="%2236648596%22">36648596)</searchLink><br />J Clin Med. 2024 Oct 09;13(19):. (PMID: <searchLink fieldCode="PM" term="%2239408078%22">39408078)</searchLink><br />Diabetes Res Clin Pract. 2025 Apr;222:112088. (PMID: <searchLink fieldCode="PM" term="%2240057043%22">40057043)</searchLink><br />Autophagy. 2025 Mar;21(3):583-597. (PMID: <searchLink fieldCode="PM" term="%2239385699%22">39385699)</searchLink><br />BMJ Open. 2022 Mar 14;12(3):e059073. (PMID: <searchLink fieldCode="PM" term="%2235288397%22">35288397)</searchLink><br />Diabetes Care. 2025 Feb 01;48(2):193-201. (PMID: <searchLink fieldCode="PM" term="%2239666579%22">39666579)</searchLink><br />Circulation. 2022 Oct 18;146(16):1210-1224. (PMID: <searchLink fieldCode="PM" term="%2236029465%22">36029465)</searchLink>
– Name: SubjectMinor
  Label: Contributed Indexing
  Group:
  Data: <i>Keywords: </i>metabolic syndrome; nephrolithiasis; pathophysiology; sodium–glucose cotransporter 2 inhibitors; urolithiasis
– Name: NumberCAS
  Label: Substance Nomenclature
  Group: ID
  Data: 0 (Sodium-Glucose Transporter 2 Inhibitors)
– Name: DateEntry
  Label: Entry Date(s)
  Group: Date
  Data: <i>Date Created: </i>20260924 <i>Date Completed: </i>20260924 <i>Latest Revision: </i>20260928
– Name: DateUpdate
  Label: Update Code
  Group: Date
  Data: 20260928
– Name: PubmedCentralID
  Label: PubMed Central ID
  Group: ID
  Data: PMC13609381
– Name: DOI
  Label: DOI
  Group: ID
  Data: 10.3390/medsci14050555
– Name: AN
  Label: PMID
  Group: ID
  Data: 42783428
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=cmedm&AN=42783428
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3390/medsci14050555
    Languages:
      – Code: eng
        Text: English
    Subjects:
      – SubjectFull: Diabetes Mellitus, Type 2 drug therapy
        Type: general
      – SubjectFull: Diabetes Mellitus, Type 2 complications
        Type: general
      – SubjectFull: Humans
        Type: general
      – SubjectFull: Sodium-Glucose Transporter 2 Inhibitors therapeutic use
        Type: general
      – SubjectFull: Sodium-Glucose Transporter 2 Inhibitors pharmacology
        Type: general
      – SubjectFull: Sodium-Glucose Transporter 2 Inhibitors adverse effects
        Type: general
      – SubjectFull: Nephrolithiasis drug therapy
        Type: general
    Titles:
      – TitleFull: SGLT2 Inhibitors in Nephrolithiasis: Emerging Evidence and What Urologists Need to Know.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Ivănuță M
      – PersonEntity:
          Name:
            NameFull: Puia D
      – PersonEntity:
          Name:
            NameFull: Ivănuță AM
      – PersonEntity:
          Name:
            NameFull: Haută A
      – PersonEntity:
          Name:
            NameFull: Nistor I
      – PersonEntity:
          Name:
            NameFull: Pricop C
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 09
              M: 09
              Text: 2026 Sep 09
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2076-3271
          Numbering:
            – Type: volume
              Value: 14
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: Medical sciences (Basel, Switzerland)
              Type: main
ResultId 1